Abstract
A newly published study suggests that medication treatments that improve substance use outcomes in patients with alcohol use disorder (AUD) convey another important benefit: they can reduce the incidence of alcohol-associated liver disease (ALD) and can delay its progression in individuals already with ALD. Also of note, the liver-related benefits of medications for AUD appear to extend to treatments that have shown promise for AUD but are limited to off-label use, such as topiramate and gabapentin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
